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Take home message (256/256 characters):
Composition of nasopharyngeal microbiota during LRTI in children is related to recurring 
respiratory symptoms in the next months, as well as to incomplete microbiota recovery. 
Future research may pinpoint host and microbial predictors of clinical outcomes.   
 
ABSTRACT 
Childhood lower respiratory tract infections (LRTI) are associated with dysbiosis of the 
nasopharyngeal microbiota, and persistent dysbiosis following the LRTI may in turn be 
related to recurrent or chronic respiratory problems.  
Therefore, we aimed to investigate microbial and clinical predictors of early recurrence of 
respiratory symptoms as well as recovery of the microbial community following hospital 
admission for LRTI in children. 
To this end, we collected clinical data and characterized the nasopharyngeal microbiota of 
154 children (4 weeks-5 years old) hospitalized for a LRTI (bronchiolitis, pneumonia, 
wheezing illness, or mixed infection) at admission and 4-8 weeks later. Data were compared 
to 307 age-, gender- and time-matched healthy controls. 
During follow-up, 66% of cases experienced recurrence of (mild) respiratory symptoms. In 
cases with recurrence of symptoms during follow-up, we found distinct nasopharyngeal 
microbiota at hospital admission, with higher levels of Haemophilus influenzae/haemolyticus, 
Prevotella oris and other gram-negatives and lower levels of Corynebacterium 
pseudodiphtheriticum/propinquum and Dolosigranulum pigrum compared to healthy controls. 
Furthermore, in cases with recurrence of respiratory symptoms, recovery of the microbiota 
was also diminished. Especially in cases with wheezing illness we observed a high rate of 
recurrence of respiratory symptoms, as well as diminished microbiota recovery at follow-up.   
Together, our results suggest a link between the nasopharyngeal microbiota composition 
during LRTI and early recurrence of respiratory symptoms, as well as diminished microbiota 
recovery after 4-8 weeks. Future studies should investigate whether (speed of) ecological 
recovery following childhood LRTI is associated with long-term respiratory problems. 




Lower respiratory tract infections (LRTIs) remain a leading cause of illness in early childhood, 
and are a risk factor for the development of recurrent and even chronic respiratory problems 
[1–3]. For instance, approximately half of infants with bronchiolitis will subsequently 
experience recurrent wheezing episodes [4], which may persist for years and might 
eventually develop into asthma [5]. Also, health-related quality of life may remain 
substantially decreased for months or even years following a LRTI in both children [6] and 
adults [7]. Causes of respiratory problems following a LRTI remain largely unknown, but 
emerging evidence suggests that the upper respiratory tract (URT) microbiota may play a 
role [8, 9].  
As expected, during a LRTI, the microbial communities of the respiratory tract differ strongly 
from those of healthy, matched controls, with increased presence of potential pathogens 
(‘pathobionts’) like Streptococcus pneumoniae and Haemophilus influenzae, and decreased 
presence of presumed beneficial bacteria like Corynebacterium and Dolosigranulum [10–13]. 
However, microbiota ‘recovery’ following a LRTI is not extensively studied. One case-control 
study has shown that the abundance of pathobiont Haemophilus decreased to normal levels 
within a month [11]. Conversely, a longitudinal study demonstrated persistent enrichment 
with Moraxella up to 6 months after a LRTI [14]. Furthermore, in a prospective cohort of 
infants with bronchiolitis, increased nasal levels of Moraxella and Streptococcus in the weeks 
directly following hospitalization were associated with recurrent wheeze at the age of 3 years, 
suggesting that persistent microbial ‘dysbiosis’ may contribute to long-term respiratory 
outcomes following a LRTI [8].  
Using a matched case-control design, we have previously demonstrated significant 
aberrations of the nasopharyngeal microbial community at time of hospital admission for 
childhood LRTI, when compared to asymptomatic age-, gender- and time-matched controls 
[13]. Currently, we extend our analysis to 4-8 weeks follow-up, and demonstrate that early 
 
recurrence of respiratory symptoms is related to the nasopharyngeal microbial community 
composition at times of LRTI as well as to impaired microbiota recovery following LRTI.  
METHODS 
We refer to our previous publication on this cohort [13] for details on study design and 
microbiota analysis, and to the online data supplement for details on statistical analysis. Data 
are available from the NCBI Sequence Read Archive database (BioProject ID 
PRJNA428382). 
Study design 
We enrolled 154 cases aged 4 weeks to 5 years old, hospitalized for a LRTI, and 307 age-, 
time- and gender-matched, healthy controls from the community (1:2 ratio except for 1 case). 
Age, season and gender are known to influence microbiota composition [15–17], and were 
therefore used as matching criteria to avoid confounding. Nasopharyngeal swabs were 
obtained from cases at hospital admission and 4-8 weeks after discharge during a follow-up 
visit to the outpatient clinic or at home. Nasopharyngeal swabs from controls were obtained 
once during a home visit within 2 weeks from case admission (Figure S1). Extensive 
information on medical history, lifestyle and environment was collected from all participants 
using questionnaires. From cases, we also collected clinical data during admission and at 
follow-up. Two expert paediatricians independently grouped cases into 3 major LRTI 
phenotypes (pneumonia, bronchiolitis, and wheezing illness) based on medical records. 
Cases with an unclear or overlapping phenotype were classified as mixed infection. 
Recurrence of respiratory symptoms was defined as a parent-reported new episode of one or 
more respiratory symptoms (including rhinorrhoea, wheezing, earache, sore throat, 
coughing, hoarseness, and ‘other’ respiratory symptoms) between hospital discharge and the 
follow-up visit 4-8 weeks later. The study was approved by the Dutch National Ethics 




Bacterial DNA was isolated and quantified as previously described [17–19], with the following 
minor modifications: 16S Real Time PCR was conducted using TAMRA probe 16S-P1 (FAM-
ATT AGA TAC CCT GGT AGT CCA-TAMRA) (Life Technologies, Carlsbad, CA) and a PCR 
mixture containing 12.5 µl 2x Taqman universal master mix (Life Technologies, Carlsbad, 
CA), 1 µl of each primer (10 µM), 1 µl of the probe (5 µM), 6.5 µl HPLC graded water 
(Instruchemie, Delfzijl, Netherlands) and 3 µl of template DNA, on the StepOnePlus System 
(Applied Biosystems, Foster City, CA). Almost all samples (>99%) contained sufficient DNA 
for reliable analysis (Figure S1). Following, amplicon libraries of the 16S-rRNA gene (V4 
region) were generated, and sequencing was executed on the Illumina MiSeq platform 
(Illumina Inc., San Diego, CA). Bioinformatic processing was performed as previously 
described [20, 21]. Contaminating sequences were identified using the decontam R-package, 
using their relation to bacterial biomass (frequency method) and their presence/absence in 
samples versus DNA isolation controls and PCR blanks (prevalence method) [22]. In total, 21 
OTUs were identified as contaminants, and were removed prior to downstream analyses 
(Table S1). Each operational taxonomic unit (OTU) was assigned taxonomy and a rank 
number based on its abundance. Double annotations were assigned to OTUs that could be 
annotated to both species. Presence of Streptococcus pneumoniae, Staphylococcus aureus, 
Haemophilus influenzae and Moraxella catarrhalis was confirmed by quantitative PCR. Viral 
presence was detected by qualitative multiplex Real Time PCR (RespiFinder SMARTfast 22, 
Maastricht, Netherlands). 
Statistical analysis 
Data analysis was performed in R version 3.4.3. Case-control comparisons accounted for 
matching. P-values or Benjamini-Hochberg adjusted q-values below 0.050 were considered 
statistically significant. Chi-square and Wilcoxon tests were used to compare host 
characteristics between cases with and without recurrence of respiratory symptoms during 
follow-up. Independent relationships between antibiotic treatment, LRTI phenotype, age, and 
 
recurrence of respiratory symptoms during follow-up were assessed using multivariable 
logistic regression, including pairwise interactions and correcting for follow-up time. 
Conditional logistic regression was used to compare viral presence between cases and 
controls. 
Alpha diversity was assessed by the Chao1 index for microbial richness and the Shannon 
index for diversity (phyloseq [23]), and significance of differences between cases and 
controls was evaluated using linear mixed-effect models. Microbiota recovery was 
considered complete when the overall microbial composition was comparable between cases 
after 4-8 weeks follow-up and matched controls, which was evaluated by permutational 
analysis of variance (PERMANOVA) on the Bray-Curtis dissimilarity matrix (vegan [24]). We 
similarly analysed differences in microbial diversity at time of admission between cases with 
and without subsequent recurrence of respiratory symptoms, adjusting for age, gender and 
month of hospital admission. 
Discriminant OTUs between cases and controls were identified by combining significant 
results from metagenomeSeq analysis [25] and cross-validated VSURF analysis [26], which 
were then filtered at a fold change (FC) of above 1.5 or below 0.5 (i.e. a 50% change).  
Stratified analyses were performed of microbiota recovery in relation to recurrence of 
respiratory symptoms during follow-up, LRTI phenotype, antibiotic treatment, and viral 
presence. In these stratified analyses, differential abundance testing was limited to the top 
100 highest-ranked OTUs, because false positive results in low abundant OTUs are a known 
risk of metagenomeSeq analysis with smaller group sizes [27]. 
 
RESULTS 
Clinical and microbial factors during LRTI were associated with early recurrence of 
respiratory symptoms 
 
Cohort characteristics were detailed previously [13]. Follow-up data were available for 149 
(97%) cases, with a median follow-up time of 39 days [IQR 35-46] (Figure S1). In the 4-8 
weeks following hospital discharge, 98 (66%) cases experienced recurrence of respiratory 
symptoms (from here on called recurrence of symptoms) (Table S2). Of these cases, 57 
(58%) specified at least 2 different respiratory symptoms, and 47 (48%) also reported fever 
(>38°C).  Furthermore, 41 cases (42%) consulted a physician, and 8 cases (8%) received 
antibiotics for these symptoms. Follow-up time was significantly longer in cases with 
recurrence of respiratory symptoms (p=0.015). Cases with and without recurrence of 
symptoms during follow-up were not significantly different in terms of baseline characteristics 
including age, lifestyle and environmental factors, medical history, and clinical findings such 
as LRTI phenotype and antibiotic treatment (Table 1). However, when age, LRTI phenotype 
and antibiotic treatment were included in a multivariable model as predictors of recurrence, 
we found a borderline significant, independent association between a diagnosis of wheezing 
illness and an increased rate of subsequent recurrence of respiratory symptoms (β=1.19 
compared to pneumonia, 95% CI -0.097-2.54, p=0.074). Furthermore, an independent 
positive association was found between antibiotic treatment during admission and 
subsequent recurrence of respiratory symptoms (β=2.47, 95% CI 0.52-4.86, p=0.023), but 
this effect diminished with increasing age (interaction age and antibiotics: β=-0.078, 95% CI -
0.15- -0.013, p=0.028)  (Table S3). Viral presence, number of viruses and detection of 
respiratory syncytial virus (RSV) or Human rhinovirus (HRV) was not significantly different 
between cases with and without recurrence (Table 1). 
In this cohort, significant differences in the microbial community composition between cases 
at admission and controls were previously shown, with especially increased abundance of 
pathobionts Haemophilus influenzae/haemolyticus and S. pneumoniae, and decreased 
abundance of presumed beneficial bacteria like Moraxella catarrhalis/nonliquefaciens, 
Dolosigranulum pigrum and Corynebacterium pseudodiphtheriticum/propinquum [13]. Here, 
a modestly lower Shannon diversity at time of admission was related to a higher rate of 
 
recurrence of symptoms, even after adjusting for age, gender and month of hospital 
admission (p=0.049; Figure 1A). Furthermore, the overall microbial community composition 
at time of admission was significantly different between cases with versus cases without 
subsequent recurrence of symptoms, independent of age, gender and month of hospital 
admission (R2: 0.020, p=0.012) (Figure 1B), though not correlated with the severity of 
recurrence of symptoms (i.e. number of symptoms (1 or >1), presence of fever, or the 
parents’ decision to consult a physician during follow-up (data not shown)). Cases with 
recurrence of symptoms had higher abundances of gram-negatives like H. 
influenzae/haemolyticus, Prevotella oris, Actinomyces and Fusobacterium species and lower 
abundances of health-associated C. pseudodiphtheriticum/propinquum and D. pigrum at time 
of admission compared to controls. On the other hand, cases without recurrence had higher 
abundances of amongst others gram-positives Staphylococcus aureus/epidermidis and S. 
pneumoniae at admission compared to controls (Table 2 and Figure S2).  
 
Nasopharyngeal microbiota and viral profiles after recovery from LRTI 
We also aimed to study remaining differences in microbial community diversity and 
composition between recovered cases and controls. In general, samples obtained 4-8 weeks 
after hospital discharge showed significantly higher microbial richness in (former) cases 
when compared to controls (p=0.042), while Shannon diversity and biomass were 
comparable (Figure S3). Furthermore, despite the observed major differences in the overall 
microbial community composition at time of infection, after 4-8 weeks the microbiota of 
recovered cases had become more similar to controls, and only a small, non-significant 
difference remained (R2: 0.004, p=0.080; Figure 2A-B). On the OTU level, we observed 15 
OTUs that were significantly differentially abundant between recovered cases and controls 
(Table 3 and Figure S4). Of these, Moraxella species and Helcococcus were already 
underrepresented at admission, and remained underrepresented in recovered cases, 
 
whereas various gram-negative species including H. influenzae/haemolyticus, P. oris, and 
Neisseria lactamica remained overrepresented in recovered cases compared to controls.  
Assessment of microbiota recovery in relation to recurrence of respiratory symptoms, 
showed that when compared to matched controls, cases with recurrence of symptoms during 
follow-up had a significantly higher microbial richness at the end of follow-up (p=0.034; 
Figure S5A). This difference in microbial richness was not present between cases without 
recurrence of symptoms and their matched controls. Also, on microbial community 
composition level, the microbiota composition had failed to normalize in cases with 
recurrence of respiratory symptoms during follow-up (R2: 0.008, p=0.028), while in cases 
without recurrence the microbiota were comparable to controls (R2: 0.005, p=0.50). 
Especially the abundances of H. influenzae/haemolyticus, Neisseria, P. oris, and 
Porphyromonas were persistently increased after recovery in cases with recurrence of 
symptoms during follow-up compared to controls, while in cases without recurrence, 
abundance of S. aureus/epidermidis and N. lactamica were increased after recovery 
compared to controls (Figure S5B).  
Viral presence at time of admission and after recovery was available for 70 cases and for 
139 corresponding controls. As described previously [13], 97% of cases tested positive for 
any virus at time of admission versus 85% of controls (p=0.019). At follow-up, 91% of 
(former) cases were virus-positive, which was not significantly different from controls. RSV 
detection was higher in cases at time of admission compared to controls (40% vs. 4%; 
p<0.001), but had normalized after recovery (3%). Interestingly, in recovered cases, HRV 
detection was more common (80%) than at time of admission (57%, p=0.006), though 
comparable to controls (70%; Figure S6). Detection of other respiratory viruses was low and 
not significantly different between cases and controls following recovery. 
Microbiota recovery depends on LRTI phenotype, but not on antibiotic treatment or type of 
virus 
 
Next, we used stratified analyses to investigate whether microbiota recovery was related to 
antibiotic treatment, LRTI phenotype or viral presence at time of admission. In total, 43 (28%) 
cases were treated with antibiotics (33 beta-lactam, 10 macrolide) during admission. 
Interestingly, only cases not treated with antibiotics showed significantly higher microbial 
richness after follow-up compared to controls (p=0.001), while no differences in Shannon 
diversity were observed in either group compared to their respective controls (Figure S7A). 
Microbiota composition at follow-up also showed little difference between both antibiotic-
treated and not antibiotic-treated cases and their respective controls (treated cases versus 
controls R2: 0.007, p=0.47; non-treated cases versus controls R2: 0.005, p=0.17).  
Regarding LRTI phenotype, 57 (37%) cases were classified as bronchiolitis, 37 (24%) as 
pneumonia, 34 (22%) as wheezing illness, and 26 (17%) as mixed infection. Only (former) 
bronchiolitis cases had significantly increased microbial richness after follow-up compared to 
matched controls (p=0.013), though a similar trend was observed for former wheezing illness 
cases (p=0.088; Figure S7B). Furthermore, only (former) wheezing illness cases still showed 
a trend towards a different overall microbial community composition at follow-up compared to 
their respective controls (R2: 0.023, p=0.072; Figure 3). As aforementioned, cases with 
wheezing illness had the highest incidence of recurrence of respiratory symptoms, while 
cases with pneumonia had the lowest incidence (Table 1). On OTU level, we observed that 
cases recovered from wheezing illness had increased levels of Streptococcus anginosus, 
and gram-negatives like P. oris, Porphyromonas and Neisseria, which were all also 
associated with recurrence (Figure 4). By contrast, cases recovered from pneumonia had 
increased levels of Klebsiella, Neisseriaceae, and gram-positives S. aureus/epidermidis and 
Kocuria, possibly related to antibiotic selection (Figure S8). 
Finally, we stratified the analysis based on the most prevalent viruses at time of LRTI, i.e. 
RSV and HRV, which were detected in 72 (47%) and 73 (47%) cases, respectively, to rule 
out virus-mediated effects on microbiota recovery. Cases recovered from a RSV-associated 
LRTI had no significant differences in microbial richness, diversity or the overall microbial 
 
composition compared to their matched controls (R2=0.003, p=0.624). Cases recovered from 
a HRV-associated LRTI also showed no significant differences in overall microbial 
composition compared to controls (R2=0.008, p=0.165), though they had a slightly higher 




LRTI is strongly associated with dysbiosis of the nasopharyngeal microbiota [13]. Here, we 
found in children hospitalized for acute LRTI that lower microbial diversity and the overall 
microbial community composition in the nasopharynx were modestly associated with 
subsequent recurrence of even very mild respiratory symptoms within 1-2 months. 
Specifically, we identified gram-negatives like H. influenzae/haemolyticus, P. oris and 
Actinomyces species as potential biomarkers of an increased risk of recurrence of respiratory 
symptoms, and gram-positives like S. aureus/epidermidis and S. pneumoniae as potential 
biomarkers of a reduced risk.  
These findings add to a small but growing body of literature suggesting that host-microbial 
interactions during and following acute (L)RTI may contribute to short- and long-term 
respiratory outcomes.  Previously, Neumann et al. found in noses of infants with their first 
RTI that lower microbial diversity and increased levels of bacterial families Moraxellaceae or 
Streptococcaceae were associated with persistent respiratory symptoms [28]. Also in the 
nasal niche, Mansbach et al. related persistently increased levels of Moraxella and 
Streptococcus in the weeks following hospitalization for bronchiolitis in infancy to persistent 
wheeze at the age of 3 years [8]. In case of RSV infection, increased nasopharyngeal levels 
of gram-negatives including H. influenzae have been associated with a pro-inflammatory 
systemic immune response with enhanced neutrophil recruitment and activation, and 
increased disease severity [29, 30]. Correlates with clinical outcomes during recovery remain 
 
unknown, but a severity-dependent relationship between RSV bronchiolitis and the risk of 
recurrent wheezing and asthma has been described [31]. Moreover, Haemophilus-dominated 
nasopharyngeal microbiota during RSV infection has also been related to increased viral 
load [11]  and delayed clearance [32], which might also contribute to persistent inflammation, 
slower recovery and more respiratory morbidity. Finally, in healthy infants, increased influx 
into the nasopharynx of gram-negatives typically found in the mouth, like Prevotella, 
Neisseria and Fusobacterium, has also been associated with higher susceptibility to RTIs in 
general [20, 33]. Alternatively, gram-positive commensals might dampen inflammatory 
responses. For instance, S. epidermidis was shown to enhance mucosal innate immune 
responses in the nose and to thereby confer resistance to viral infection [34]. Moreover, 
dominance of Corynebacterium and Dolosigranulum in the infant nasopharyngeal microbiota 
has been related to decreased incidence of RTIs [35]. Future studies should therefore 
investigate whether antibiotic treatment targeted at gram-negatives and/or preservation or 
supplementation of gram-positive commensals may prevent recurrence of respiratory 
symptoms after LRTI and improve long-term respiratory outcomes.  
In general, we observed that the nasopharyngeal microbiota had recovered 4-8 weeks after 
hospitalization for LRTI, though subtle differences remained including a persistently lower 
abundance of Moraxella than seen in healthy controls. Remarkably, this is opposite to 
observations by Teo and colleagues [14]. This study had an unmatched design, later timing 
of post-LRTI sampling and a different geographic location, but the discrepancy with our 
findings might also reflect biological differences between their cohort at high risk for atopy 
and our unselected cohort. In line with our findings, Kaul and colleagues recently 
demonstrated that in some adult patients with acute influenza infection, microbial 
communities returned to a healthy state within 22 days from hospital admission [36]. It thus 
appears that the URT microbiota are resilient, but the speed of recovery differs between 
individuals. In addition, we observed that children with early recurrence of respiratory 
symptoms following LRTI also had diminished microbiota recovery, despite a longer follow-
 
up duration and more time for the microbiota to recover. The association between longer 
follow-up duration and recurrence of respiratory symptoms may be directly linked, though 
also explained by the fact that children had to be asymptomatic at the time of sampling, and 
as a consequence the follow-up visit was postponed when symptoms were present at that 
moment. Irrespectively, given the high incidence of symptom recurrence in our cohort, we 
theorize that while the microbiota gradually recover following LRTI, resistance to viral 
infection or bacterial pathobiont acquisition and overgrowth might remain diminished for 
some time, resulting in a (temporarily) elevated risk of new infections upon pathobiont 
exposure. Aberrant airway immune profiles in asymptomatic neonates and during RSV 
infection were previously associated with presence and abundance of gram-negatives 
colonizing the respiratory tract [29, 37, 38], and might mediate this association, but this 
remains to be investigated. An alternative hypothesis is, however, that children may be 
genetically predisposed to both microbiota shifts and development of RTIs. For example, 
genetic variants were previously shown to increase susceptibility to otitis media by modifying 
the middle ear microbiome [39]. This would mean our findings are correlative in nature more 
than causally linked. Future studies should therefore take genetic factors into consideration 
to understand the potential mechanisms underpinning our findings.   
Importantly, we observed early recurrence of respiratory symptoms followed by diminished 
microbiota recovery especially in children with wheezing illness, whereas microbiota changes 
during LRTI were previously shown to be phenotype-independent [13]. Together, our findings 
suggest that especially in children with inflammation-driven illness, the nasopharyngeal 
microbiota may have more limited property to recover to a state comparable to healthy, 
matched controls. This is in line with other observational studies where LRTIs accompanied 
by wheezing symptoms were particularly associated with aberrant respiratory microbiota 
development [14] and with later-life persistent wheeze and development of asthma [2, 3]. We 
speculate that wheezing illness patients, who were older than patients with a different LRTI 
phenotype, may have had a more elaborate medical history with LRTIs and atopic 
 
symptoms, which may have resulted in reduced resilience of the microbiota. Alternatively, 
wheezing illness patients often received treatment with inhaled corticosteroids upon hospital 
discharge, which might also have affected microbiota recovery [40, 41]. Unfortunately, limited 
power hampered us to study the effect of inhaled corticosteroids on the respiratory 
microbiota and its recovery. Antibiotic-treated patients also had an increased risk of 
subsequent recurrence, particularly the younger ones. Dutch physicians tend to reserve 
antibiotic treatment for the more severely ill patients. Therefore, we cannot rule out that this 
correlation between antibiotic treatment and recurrence might be influenced by more severe 
disease and accompanying inflammation. Following, the restorative capacity of the 
nasopharyngeal microbiota appeared in general not related to antibiotic treatment, though we 
had insufficient power to test if younger antibiotic-treated children may be more prone to 
prolonged microbiota disturbance, as has been suggested in previous reports [42, 43]. 
Finally, the type of virus detected at time of admission seemed unrelated to recurrence of 
respiratory symptoms and microbiota recovery in this cohort, despite known relationships 
between LRTIs associated with RSV or HRV and chronic respiratory morbidity [44]. 
Strengths of our study include the strictly matched case-control design that allowed us to 
preclude bias from age, gender and seasonality. Furthermore, inclusion of children up to 5 
years old, hospitalized for all LRTI phenotypes allowed us to perform in-depth analyses. 
However, several limitations need to be acknowledged. We were unable to directly study the 
lung microbiota during recovery, but the high concordance between the microbiota in 
nasopharyngeal and endotracheal samples at time of LRTI in young children implies that the 
nasopharyngeal microbiota provides a valid proxy [13]. Furthermore, follow-up of cases 
entailed only one timepoint, and therefore, we could not distinguish at what pace microbial 
recovery occurred, and whether microbial recovery was still ongoing. Follow-up duration also 
varied and was different between cases with and without recurrence. However, since the 
microbiota of cases with recurrence had even more time to recover, this strengthens the 
likelihood that recurrence of respiratory symptoms following LRTI is associated with 
 
diminished microbiota recovery. Lastly, for our analyses of recurrence we relied on parental 
report of respiratory symptoms since hospital discharge, which may have introduced recall 
bias. 
In conclusion, our results suggest that the composition of the nasopharyngeal microbiota 
during acute LRTI in children may increase susceptibility to new respiratory symptoms in the 
months following, while the microbiota gradually recover. Future prospective studies with 
higher resolution and longer follow-up duration, especially focused on recovery from LRTI in 
high-risk groups of recurrent or chronic respiratory morbidity, are required to confirm and 
nuance our findings, and should strive to combine host and microbial factors into prediction 
models of (long-term) clinical outcomes. The current work may be a stepping stone to 
improved understanding of respiratory outcomes after childhood LRTI and potentially provide 
input for clinical studies on methods to alleviate recurrent respiratory problems.  
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Figure 1 legend 
Figure 1: Nasopharyngeal microbiota during LRTI was associated with early 
recurrence of respiratory symptoms  
(A) Alpha diversity measures Chao1 index and Shannon diversity index estimated at time of 
admission for cases with compared to without recurrence of respiratory symptoms during 
follow-up. Boxes denote means with 95% confidence intervals. Significance was tested by 
linear models adjusting for age, gender and month of admission, and is indicated by *: 
p<0.05. (B) Nonmetric multidimensional scaling biplot based on Bray-Curtis dissimilarity 
depicts nasopharyngeal microbiota composition at time of admission for cases with 
compared to without recurrence of respiratory symptoms during follow-up, combined with the 
top 10 operational taxonomic units (OTUs) with highest relative abundance in the entire 
cohort. Ellipses represent the standard deviation of all points within a sub-cohort. 
Significance was tested using permutational analysis of variance (PERMANOVA), adjusting 
for age, gender and month of hospital admission.  
 
Figure 2 legend 
Figure 2: Nasopharyngeal microbiota recovery following LRTI 
(A) Nonmetric multidimensional scaling biplot based on Bray-Curtis dissimilarity depicts 
nasopharyngeal microbiota composition for cases at admission, cases at follow-up 
(recovery), and controls, combined with the top 10 operational taxonomic units (OTUs) with 
highest relative abundance in the entire cohort. Time (t) in days between admission and the 
follow-up visit was reported as median [IQR]. Ellipses represent the standard deviation of all 
points within a sub-cohort. Significance was tested using permutational analysis of variance 




Figure 3 legend 
Figure 3. Microbiota recovery depended on infection phenotype. 
Nonmetric multidimensional scaling plots based on Bray-Curtis dissimilarity depict 
nasopharyngeal microbiota composition for cases at admission, cases at follow-up 
(recovery), and controls, for each of the 4 phenotypes. Ellipses represent the standard 
deviation of all points within a sub-cohort. Significance was tested using permutational 
analysis of variance (PERMANOVA).  
 
Figure 4 legend 
Figure 4. Discriminant OTUs between cases recovered from wheezing illness and 
matched controls. 
Volcano plot of differentially abundant OTUs between cases recovered from wheezing illness 
and controls. Significance was assessed by metagenomeSeq analysis and cross-validated 
VSURF analysis limited to the top 100 most highly ranked OTUs, and combined results were 
filtered at a fold change of at least 1.5 or below 0.5. OTUs marked by an asterisk were 
identified by cross-validated VSURF analysis. Results of data points falling beyond the limits 
of the plot: Helcococcus log2FC -5.93, adjusted p-value (log10) 13.48; Janthinobacterium 




Table 1. Characteristics of cases with and without recurrence of respiratory symptoms 
during 4-8 weeks follow-up. 
  Recurrence   No recurrence  P-value 
   n  98  51  
Basics    
   Age (months)   12.7 [5.5, 21.6]  16.1 [3.5, 32.1] 0.481 
   Girl  39 (39.8)   21 (41.2)  1.000 
   Season of sampling     0.679 
      Spring  13 (13.3)   7 (13.7)   
      Summer  20 (20.4)   14 (27.5)   
      Autumn  10 (10.2)   3 (5.9)   
      Winter  55 (56.1)   27 (52.9)   
   Born at term  90 (91.8)   47 (92.2)  1.000 
   Mode of delivery     0.190 
      vaginal  76 (77.6)   43 (84.3)   
      elective caesarean section  9 (9.2)   6 (11.8)   
      emergency caesarean section  13 (13.3)   2 (3.9)   
Lifestyle and Environmental Factors    
   Breastfeeding >3 months  38 (38.8)   18 (35.3)  0.812 
   Day care attendance  65 (66.3)   28 (54.9)  0.235 
   Tobacco smoke exposure   19 (19.4)   14 (27.5)  0.359 
   Number of siblings  1.0 [0.2, 2.0]  1.0 [0.0, 2.0] 0.654 
Medical History    
   Previous LRTI*   29 (29.6)   11 (21.6)  0.393 
   Previous hospitalization for RTI†   29 (29.6)   8 (15.7)  0.096 
   Prior wheezing   25 (25.5)   11 (21.6)  0.740 
Clinical Data    
   Main discharge diagnosis     0.408 
      bronchiolitis  37 (37.8)   19 (37.3)   
      indeterminate  18 (18.4)   8 (15.7)   
      pneumonia  18 (18.4)   15 (29.4)   
      wheezing  25 (25.5)   9 (17.6)   
   Antibiotic treatment during admission   25 (25.5)   14 (27.5)  0.953 
   Prednison during admission  16 (16.3)  9 (17.6) 1.000 
   Follow-up time (days after admission)  42.0 [36.0, 49.0]  39.0 [34.5, 44.0] 0.015 
Viral detection at admission    
   Any virus (%)  94 (98.9)  47 (94.0) 0.232 
   Respiratory syncytial virus (%)  42 (44.2)  28 (56.0) 0.240 
   Human rhinovirus (%)  51 (53.7)  21 (42.0) 0.245 
   Number of viruses (median [IQR])  1.0 [1.0, 2.0]  1.0 [1.0, 2.0] 0.299 
Data are n (%) or median [IQR]. Data were acquired from parent questionnaires and medical 
records. Viral presence was detected by multiplex PCR in nasopharyngeal samples obtained 
at admission. P-values were calculated by chi-square tests or Wilcoxon rank-sum tests. 
* lower respiratory tract infection; † respiratory tract infection. 
  
 
Table 2: Biomarker species during acute LRTI for subsequent recurrence of 
respiratory symptoms 
* operational taxonomic unit; † fold change; ‡ metagenomeSeq analysis; § VSURF analysis.  
  
Differentially abundant at 
admission 
OTU* FC† Significant in 
In cases with subsequent 
recurrence of respiratory 
symptoms vs. controls 
Haemophilus 
influenzae/haemolyticus (2) 
5.97 ms‡ + V§ 
Fusobacterium (83) 2.57 ms 
Prevotella oris (45) 2.31 ms 
Actinomyces graevenitzii (68) 1.88 ms + V 
Fusobacterium (74) 1.76 ms 
Actinomyces johnsonii (75) 1.76 ms + V 
Actinomyces odontolyticus (48) 1.66 ms + V 





In cases without subsequent 
recurrence of respiratory 
symptoms vs. controls 
Neisseria lactamica (19) 2.97 ms + V 
Staphylococcus aureus/epidermidis 
(7) 
2.38 ms + V 
Streptococcus pneumoniae (3) 2.31 V 
Atopobium (100) 1.99 ms 
Klebsiella (11) 1.75 ms + V 
Halomonas (14) 1.57 ms 
Prevotella melaninogenica (16) 1.54 V 
Prevotella nanceiensis (25) 0.49 ms 
Neisseria (9) 0.43 ms + V 
 
Table 3. Discriminant OTUs for cases during acute LRTI and after 4-8 weeks follow-up 
compared to controls. 
* operational taxonomic unit; † fold change; ‡ metagenomeSeq analysis; § VSURF analysis; 
ll not significantly different. 
 
  
  Cases at admission 
vs. controls 
Cases at recovery 
vs. controls 
Association OTU* FC† Significant in FC Significant 
in 
Admission Lactococcus lactis (67) 2.06 ms‡ + V§ ns ll ns 
Corynebacteriaceae (161) 1.83 ms + V ns ns 
Abiotrophia (111) 1.66 ms + V ns ns 
Corynebacterium (62) 1.64 ms ns ns 
Megasphaera (137) 1.62 ms ns ns 
Fusobacterium (74) 1.61 ms ns ns 
Actinomyces (48) 1.56 ms ns ns 
Fusobacterium (83) 1.53 ms ns ns 
Actinomyces graevenitzii (68) 1.52 ms + V ns ns 
Acinetobacter soli (125) 1.51 ms ns ns 
Actinomyces johnsonii (75) 1.51 ms ns ns 
Dolosigranulum pigrum (5) 0.43 ms ns ns 






3.85 ms + V 1.69 V 
Neisseria lactamica (19) 2.22 ms + V 1.96 ms + V 
Prevotella oris (45) 2.03 ms 1.72 ms + V 
Moraxella (54) 0.32 ms + V 0.45 ms + V 
Moraxella (58) 0.19 ms + V 0.45 ms + V 
Moraxella lincolnii (6) 0.18 ms + V 0.3 ms + V 
Moraxella (84) 0.17 ms + V 0.34 ms 
Moraxella (163) 0.15 ms + V 0.39 ms + V 
Moraxella (112) 0.08 ms 1.68 ms 
Helcococcus (43) 0.07 ms 0.07 ms + V 
Recovery Neisseriaceae (15) ns ns 2.26 ms + V 
Moraxella (12) ns ns 1.83 ms 
Porphyromonas (39) ns ns 1.62 ms 
Bradyrhizobium (17) ns ns 1.54 ms + V 
Janthinobacterium lividum (23) ns ns 0.09 ms + V 
 
 
  
 
 
  
 
 
  
 
 
